TELIX PHARMACEUTICALS LIMITED (TLX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

TLX

TLX - TELIX PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 11.42
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

Telix Pharmaceuticals is a global biopharmaceutical company developing and commercialising diagnostic and therapeutic radiopharmaceuticals, principally for cancer and rare diseases.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$15.58

27 Aug
2026

0.090

OPEN

$15.40

0.58%

HIGH

$15.84

1,273,984

LOW

$15.17

TARGET
$25.06 60.8% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
TLX: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) 6.2 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 252.7 xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-3.3
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx1,246.6 M
Book Value Per Share xxxxxxxxxxxxxxx183.9
Net Operating Cash Flow xxxxxxxxxxxxxxx-26.8 M
Net Profit Margin xxxxxxxxxxxxxxx-0.89 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-1.86 %
Return on Invested Capital xxxxxxxxxxxxxxx-0.91 %
Return on Assets xxxxxxxxxxxxxxx-0.67 %
Return on Equity xxxxxxxxxxxxxxx-1.86 %
Return on Total Capital xxxxxxxxxxxxxxx2.23 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-85.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx28 M
Long Term Debt xxxxxxxxxxxxxxx672 M
Total Debt xxxxxxxxxxxxxxx700 M
Goodwill - Gross xxxxxxxxxxxxxxx298 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx213 M
Price To Book Value xxxxxxxxxxxxxxx6.09

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx86.8 M
Capex % of Sales xxxxxxxxxxxxxxx6.97 %
Cost of Goods Sold xxxxxxxxxxxxxxx584 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx635 M
Research & Development xxxxxxxxxxxxxxx266 M
Investments - Total xxxxxxxxxxxxxxx56 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

21/08/2026

1

Buy, High Risk

$31.00

98.97%

Citi sees Telix Pharmaceuticals entering a catalyst-rich period, with progress expected across Pixclara, Zircaix and TLX591 in the second half.

The broker has opened a 30-day upside Catalyst Watch, anticipating potential FDA approval for brain imaging agent Pixclara.

First-half results provided additional cost detail without major surprises, while FY26 guidance was unchanged, the analyst observes.

The broker's revenue forecast sits modestly above the US$950m-US$970m guidance range, implying around 29% growth for Precision Medicine.

The broker expects Zircaix resubmission within two months and sees potential near-term FDA approval for Pixclara.

Citi retains a Buy/High Risk rating. Target $31.

FORECAST
Citi forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -4.07 cents.
Citi forecasts a full year FY27 dividend of 0.00 cents and EPS of 6.25 cents.

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

24/08/2026

1

Overweight

$20.70

32.86%

Jarden maintains its Buy recommendation for Telix Pharmaceuticals with its target price reduced to $20.70 from $21.10 following a solid first-half FY26 result despite revenue being pre-released at the second-quarter update.

Earnings came in ahead of expectations largely due to the inclusion of US$40m of other income from Regeneron serving as an offset to operational expenditure.

This income will fund research and development increases, keeping the group on track to meet FY26 guidance of US$230m to $270m as management continues reinvesting in the pipeline.

The broker's estimates and analyst outlook highlight the upcoming Food and Drug Administration approval decision on PIXCLARA as the next key catalyst.
Access Extra Coverage Research History >

TLX STOCK CHART

FNArena News on TLX

1
Australian Broker Call *Extra* Edition – Aug 24, 2026

Aug 24 2026 - Daily Market Reports
2
FNArena Corporate Results Monitor – 21-08-2026

Aug 21 2026 - Australia
3
Rudi’s View: Upside Risk In Crowded Shorts

Aug 12 2026 - Rudi's View
4
Rudi’s View: Final Preparations For August

Aug 05 2026 - Rudi's View
5
Australian Broker Call *Extra* Edition – Jul 27, 2026

Jul 27 2026 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL’s FY26 Suggests The Downtrend Is Done

Aug 19 2026 - Australia
2
Strong Result, Can Telix Continue To Deliver?

Jul 22 2026 - Australia
3
CSL Challenges Pile On, Where’s The Upside?

May 13 2026 - Australia
4
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
5
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
6
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
7
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
8
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
9
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
10
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps